Veru Reports Fiscal 2023 Second Quarter Financial Results
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced financial results for its fiscal 2023 second quarter and provided a business update
By Veru Inc.
Published - May 11, 2023, 06:36 AM ET
Last Updated - May 02, 2024, 03:01 PM EDT
Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), includingtwo planned interim efficacy analyses
ENTADFI®product sold for $20 million, plus up to an additional potential $80 million from sales milestones
Common stock purchase agreement with Lincoln Park Capital for up to $100 million provides financial flexibility
Company reported positive preclinical data for sabizabulin for influenza induced ARDS and for poxvirus
